LOSARTAN-D4

LOSARTAN-D4 Basic information
Product Name:LOSARTAN-D4
Synonyms:2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5yl)[1,1'-biphenyl-d4]-4-yl]Methyl]-1H-iMidazole-5-Methanol;Cozaar-d4;MK-954-d4;LOSARTAN-D4;2-Butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl-2,3,5,6-d4]methyl]-1H-imidazole-5-methanol;Reaxys ID: 18951469;[2H4]-Losartan;DuP-753 D4
CAS:1030937-27-9
MF:C22H19ClD4N6O
MW:426.94
EINECS:
Product Categories:Heterocycles;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Pharmaceuticals
Mol File:Mol File
LOSARTAN-D4 Structure
LOSARTAN-D4 Chemical Properties
Melting point 184-190?C
storage temp. -20°C Freezer, Under Inert Atmosphere
solubility Chloroform (Slightly),Ethyl Acetate (Slightly), Methanol (Slightly)
form Solid
color White to Off-White
Safety Information
MSDS Information
LOSARTAN-D4 Usage And Synthesis
DescriptionLosartan-D4 is a deuterium-labeled version of Losartan, which is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with an IC50 of 20 nM. Losartan is an antagonist of the angiotensin (AT) II receptor subtype AT1 with a K i value of 5-20 nM. 
Chemical PropertiesWhite Solid
UsesAs a labelled version of Losartan, Losartan-d4 can be used as a nonpeptide angiotensin II AT1-receptor antagonist and Antihypertensive.
UsesA labelled version of Losartan, a nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive.
UsesLosartan-d4 can be intended for use as an internal standard for the quantification of Losartan by GC- or LC-mass spectrometry.
LOSARTAN-D4 Preparation Products And Raw materials
Losartan Carboxaldehyde Losartan potassium (50 MG) Losartan potassium Losartan potassium O-Acetyl Losartan N-Trityl Losartan IsoMer Losartan-d3 Carboxylic Acid Losartan N2-Glucuronide Losartan Impurity 7 N,O-Ditrityl Losartan Losartan Methyl Ether Trityl losartan Losartan carboxylic acid N-Trityl Losartan Isomer LOSARTAN-D3 Bithionol NO-LOSARTAN A Losartan

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.